

Special Issue

Chronic Pulmonary Aspergillosis

Message from the Guest Editor

Chronic pulmonary aspergillosis (CPA) is an increasingly recognised entity in patients without the classical risk factors for invasive fungal disease. It mainly complicates previously treated tuberculosis (TB) and COPD; due to the numbers of people with these conditions, the global burden of CPA is significant, particularly in low-resource settings. Despite the obvious global health implications, surprisingly little is known about the pathogenesis, diagnosis, and management of the disease. Some evidence of the presence of subtle immune defects or a genetic susceptibility to CPA has emerged. Diagnosis relies on a combination of radiological and microbiological features and clinician expertise; better validation of diagnostic tests is required. Finally, treating this disease is extremely challenging as long-term treatment is needed, there is only one class of oral agents, the azoles, and resistance develops promptly, especially in patients with extensive disease and aspergillomas. An individualised, host-targeted approach is most beneficial.

Guest Editor

Dr. Chris Kosmidis

National Aspergillosis Centre, Wythenshawe Hospital, Manchester
University NHS Foundation Trust, Manchester, UK

Deadline for manuscript submissions

closed (31 March 2021)



Journal of Fungi

an Open Access Journal
by MDPI

Impact Factor 4.0
CiteScore 8.4
Indexed in PubMed



mdpi.com/si/42687

Journal of Fungi
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jof@mdpi.com

mdpi.com/journal/

[jof](https://mdpi.com/journal/)





Journal of Fungi

an Open Access Journal
by MDPI

Impact Factor 4.0
CiteScore 8.4
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/jof)

[jof](https://mdpi.com/journal/jof)



About the Journal

Message from the Editor-in-Chief

The *Journal of Fungi* (JoF, ISSN 2309-608X) is an international, peer-reviewed, scientific, open access journal that provides an advanced forum for studies related to pathogenic fungi, fungal biology, and all other aspects of fungal research. Research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. David S. Perlin

Hackensack Meridian Health Center for Discovery and Innovation, 340
Kingsland Street, Nutley, NJ 07110, USA

Author Benefits

Open Access

— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Mycology) / CiteScore - Q1 (Ecology, Evolution, Behavior and Systematics)